John R. Horn, PharmD, FCCP and Philip D. Hansten, PharmD
References
1. Savaysa. [package insert]. Parsippany; NJ Daiichi Sankyo, Inc, 2015.
2. Bathala MS, Masumoto H, Oguma T et al. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012;40:2250-5.
3. Jonsson S, Simonsson US, Miller R et al. Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study. J Clin Pharmacol. 2015; doi: 10.1002/jcph.541. [Epub ahead of print].
4. Mendell J, Lee F, Chen S et al. The effects of the antiplatelet agents, aspirin and naproxen, on the pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. J Cardiovasc Pharmacol. 2013;62:212-12.
5. Mendell J, Zahir H, Matsushima N et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013; 13:331-42.
6. Mendell J, Chen S, He L, et al. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults. Clin Drug Investig. 2015; doi: 10.1007/s40261-015-0298-2. [Epub ahead of print].